{"meta":{"query_hash":"a4e20e8ca8af","filters":{"venue":"American Journal of Cancer"},"cohort_total":7,"direct_labels_cover":0,"predictions_cover":7,"exported":7,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/a4e20e8ca8af","api":"https://metacan.xera.ac/api/v1/cohort?venue=American+Journal+of+Cancer"},"results":[{"id":"W1488429601","doi":"10.2165/00024669-200201030-00003","title":"Hypercalcemia of Malignancy","year":2002,"lang":"de","type":"article","venue":"American Journal of Cancer","topic":"Bone health and treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Hamilton Regional Laboratory Medicine Program","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Malignancy; Calcitonin; Cancer; Calcium metabolism; Internal medicine; Endocrinology; Calcium","score_opus":0.021391365166986708,"score_gpt":0.31980981705348044,"score_spread":0.29841845188649374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1488429601","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7027107,0.2884654,0.000019224039,0.0047287913,0.0017089014,0.0001527718,0.00003847622,0.00000500363,0.0021707187],"genre_scores_gemma":[0.9252129,0.07114881,0.00050768914,0.001330445,0.0007195306,0.000003745047,7.561457e-7,0.00003008615,0.0010460351],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99796915,0.00008847811,0.000901606,0.00013896725,0.0005051122,0.00039669],"domain_scores_gemma":[0.99741054,0.000088643465,0.0014046772,0.00022442489,0.00036455417,0.00050714816],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00014046003,0.00019456988,0.0009509742,0.0001712409,0.000040352712,0.000005691342,0.0001292749,0.00005702952,0.0021234457],"category_scores_gemma":[0.000059844453,0.00015018253,0.00025939374,0.00041216536,0.00035331413,0.00007711406,0.000015314432,0.0003527189,0.0001224902],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00058179453,0.00049096707,0.25357392,0.00013895116,0.0011587846,0.00033957095,0.00087609375,0.000008996903,0.0001732607,0.000020078885,0.008603961,0.73403364],"study_design_scores_gemma":[0.021166388,0.026904225,0.45477068,0.009338167,0.0104236975,0.0006487419,0.0017021241,0.00033399242,0.005378843,0.00014469589,0.46830416,0.00088428607],"about_ca_topic_score_codex":0.000998289,"about_ca_topic_score_gemma":0.000018652003,"teacher_disagreement_score":0.73314935,"about_ca_system_score_codex":0.00023167062,"about_ca_system_score_gemma":0.00037655717,"threshold_uncertainty_score":0.9987888},"labels":[],"label_agreement":null},{"id":"W1805832649","doi":"10.2165/00024669-200605040-00002","title":"Epidermal Growth Factor Receptor Antagonists in Pancreatic Cancer","year":2006,"lang":"en","type":"article","venue":"American Journal of Cancer","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Erlotinib; Cetuximab; Pancreatic cancer; Gemcitabine; Medicine; Epidermal growth factor receptor; EGFR inhibitors; Oncology; Gefitinib; Erlotinib Hydrochloride; Internal medicine; Cancer; Pharmacology; Colorectal cancer","score_opus":0.019959407913621396,"score_gpt":0.36015438891479007,"score_spread":0.3401949810011687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1805832649","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888305,0.0031733927,0.00008006586,0.0061807116,0.00019651116,0.0001635942,0.000021037047,0.000008378449,0.0013458194],"genre_scores_gemma":[0.99228024,0.0037057642,0.0015095162,0.00066941266,0.0008246384,0.000030383315,0.0000023211423,0.000023889248,0.00095381547],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99823844,0.00013438868,0.00061857724,0.00015686757,0.0004411872,0.00041053965],"domain_scores_gemma":[0.9986971,0.00020874452,0.00045245892,0.00012748175,0.00031255608,0.0002016818],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00026856136,0.00015514252,0.0009316071,0.00024815302,0.000041175885,0.000011906168,0.00013113412,0.00005250278,0.0012477919],"category_scores_gemma":[0.000117584364,0.00011546886,0.00013322012,0.0004341594,0.00038532325,0.000102254206,0.000019066609,0.00041793438,0.000013551321],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00074120203,0.00014235896,0.97142243,0.000041303494,0.00014680535,0.00015393771,0.0001792521,0.0000107668075,0.0050616027,0.000041286203,0.003739404,0.018319624],"study_design_scores_gemma":[0.0021105679,0.000844666,0.9884384,0.0003553518,0.00016698317,0.00012738853,0.0002251921,0.00006614893,0.0017088935,0.000086688444,0.0057350886,0.00013458823],"about_ca_topic_score_codex":0.010381944,"about_ca_topic_score_gemma":0.0005844536,"teacher_disagreement_score":0.018185034,"about_ca_system_score_codex":0.00053825,"about_ca_system_score_gemma":0.001110697,"threshold_uncertainty_score":0.9996652},"labels":[],"label_agreement":null},{"id":"W1988990009","doi":"10.2165/00024669-200504020-00005","title":"Fluorouracil Formulations for the Treatment of Actinic Keratosis","year":2005,"lang":"en","type":"article","venue":"American Journal of Cancer","topic":"Nonmelanoma Skin Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; University of Toronto; Mediprobe Research (Canada); Sunnybrook Health Science Centre","funders":"","keywords":"Actinic keratosis; Medicine; Dermatology; Imiquimod; Cryotherapy; Keratosis; Fluorouracil; Erythema; Acitretin; Rosacea; Cryosurgery; Adverse effect; Clinical trial; Surgery; Acne; Chemotherapy; Psoriasis; Pharmacology; Internal medicine","score_opus":0.027949960004267214,"score_gpt":0.36492402977898963,"score_spread":0.33697406977472244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988990009","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96385735,0.01502131,0.00174127,0.018258417,0.00026311356,0.00036291854,0.000028044024,0.0000052255295,0.00046235538],"genre_scores_gemma":[0.9862334,0.007485783,0.0047385003,0.00032733302,0.0008681275,0.000052665207,4.1045848e-7,0.000013644186,0.00028014867],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992705,0.000012745335,0.00033240987,0.00006620226,0.00018429263,0.00013384582],"domain_scores_gemma":[0.99872464,0.00032858035,0.0004903632,0.00013992803,0.00025923643,0.000057277048],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000079881735,0.000091489375,0.00037958505,0.000056160035,0.00007016824,0.000004717881,0.000064435895,0.000012116933,0.00009951978],"category_scores_gemma":[0.000028579429,0.00005083409,0.00023132705,0.00014950754,0.00014299848,0.00006079122,0.000005089464,0.000053769618,0.0000011644538],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006586972,0.00015864403,0.04795303,0.0000088114875,0.00094547396,0.0000013194929,0.0015206139,0.00025713872,0.00045202937,0.000028570548,0.0016064057,0.9464093],"study_design_scores_gemma":[0.004592971,0.008132365,0.26558867,0.00014391784,0.0016551096,0.00010268531,0.00180628,0.00031149192,0.021808188,0.00004494817,0.69566244,0.00015089591],"about_ca_topic_score_codex":0.00010858959,"about_ca_topic_score_gemma":0.00014214661,"teacher_disagreement_score":0.94625837,"about_ca_system_score_codex":0.00029620266,"about_ca_system_score_gemma":0.00021683903,"threshold_uncertainty_score":0.2072954},"labels":[],"label_agreement":null},{"id":"W2059413299","doi":"10.2165/00024669-200504010-00003","title":"The Oral NK1 Antagonist Aprepitant for Prevention of Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy","year":2005,"lang":"en","type":"article","venue":"American Journal of Cancer","topic":"Nausea and vomiting management","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Aprepitant; Antiemetic; Chemotherapy-induced nausea and vomiting; Medicine; Vomiting; Nausea; NK1 receptor antagonist; Ondansetron; Anesthesia; Chemotherapy; Regimen; Granisetron; Pharmacology; Internal medicine; Oncology; Receptor; Substance P","score_opus":0.011766599754773512,"score_gpt":0.32034852165469835,"score_spread":0.30858192189992484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2059413299","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965066,0.0006213613,0.00024316808,0.002217177,0.000083687606,0.00024246427,0.0000021141532,0.0000032463113,0.000080236256],"genre_scores_gemma":[0.9959627,0.0011140914,0.0023416677,0.00026701533,0.00018023324,0.000008106891,7.0097786e-7,0.000014218839,0.00011126125],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99905694,0.000042438503,0.0004529999,0.00008938902,0.00019714213,0.00016108254],"domain_scores_gemma":[0.99896955,0.000097411146,0.0006386997,0.000087429966,0.00015632599,0.000050579867],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005249047,0.000077631754,0.00028385813,0.00008259788,0.00005366018,0.000014575791,0.00006935657,0.000013792862,0.00000674686],"category_scores_gemma":[0.000085109394,0.000053339187,0.000085859436,0.00014353484,0.00009927925,0.00007417344,0.0000144387905,0.000097823366,1.3485325e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001015429,0.0000927463,0.3472604,0.00003201808,0.00014951346,8.039575e-7,0.00025140942,0.000017793245,0.0011920839,0.000026323254,0.00024059735,0.6497209],"study_design_scores_gemma":[0.0070060757,0.0023635977,0.9703818,0.0005229617,0.00018183279,0.000006664876,0.00056103116,0.00022649404,0.0063953553,0.00009191233,0.012146059,0.00011623909],"about_ca_topic_score_codex":0.000050173934,"about_ca_topic_score_gemma":0.00009248978,"teacher_disagreement_score":0.6496047,"about_ca_system_score_codex":0.00012391369,"about_ca_system_score_gemma":0.000062389474,"threshold_uncertainty_score":0.2175109},"labels":[],"label_agreement":null},{"id":"W2088738945","doi":"10.2165/00024669-200302060-00003","title":"Pharmacologic Management of Painful Oncology Procedures in Pediatrics","year":2003,"lang":"en","type":"article","venue":"American Journal of Cancer","topic":"Pediatric Pain Management Techniques","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Hospital for Sick Children","funders":"","keywords":"Medicine; Anesthesia; Sedation; Prilocaine; Lidocaine; Propofol; Fentanyl; Alfentanil; Ketamine; Midazolam","score_opus":0.014473809833069897,"score_gpt":0.36465601077635007,"score_spread":0.3501822009432802,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2088738945","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98325807,0.00348268,0.0009679525,0.0010954188,0.0001752836,0.00038595614,0.0000015489943,0.000022704198,0.010610393],"genre_scores_gemma":[0.96706736,0.018899264,0.012745026,0.0009858265,0.00013199853,0.000026555514,2.3153135e-7,0.000013052069,0.00013066272],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99858385,0.00015485952,0.0005761475,0.00012223292,0.00033486643,0.00022802527],"domain_scores_gemma":[0.99873334,0.00009925563,0.0007996098,0.000112488815,0.00015758691,0.00009771354],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009402562,0.000114675066,0.00049056567,0.00043840843,0.000011838085,0.000002983483,0.00015073115,0.000033673536,0.00012582692],"category_scores_gemma":[0.00011209649,0.000095624244,0.0001014534,0.00082784693,0.00013740828,0.000060858925,0.000026191636,0.00024184893,0.000001205851],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005800962,0.0007064046,0.8294394,0.0005790421,0.0003248647,0.00087533303,0.00027409437,0.00019472565,0.0007418445,0.00030793884,0.0146094095,0.15136686],"study_design_scores_gemma":[0.011450034,0.010677155,0.80861545,0.00077869446,0.0031519153,0.00032773634,0.0064233667,0.00008411994,0.0037952913,0.0016699445,0.15228702,0.0007392764],"about_ca_topic_score_codex":0.000027786953,"about_ca_topic_score_gemma":0.000007707491,"teacher_disagreement_score":0.15062758,"about_ca_system_score_codex":0.0003305389,"about_ca_system_score_gemma":0.00037296614,"threshold_uncertainty_score":0.38994434},"labels":[],"label_agreement":null},{"id":"W2325094700","doi":"10.2165/00024669-200504040-00006","title":"Erlotinib","year":2005,"lang":"de","type":"article","venue":"American Journal of Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Erlotinib; Pharmacology; Internal medicine; Cancer","score_opus":0.00928745523564239,"score_gpt":0.3634912078921711,"score_spread":0.3542037526565287,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2325094700","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.52543664,0.41054368,0.00037538385,0.049628485,0.0053110616,0.0004049063,0.0001003934,0.000024396704,0.008175066],"genre_scores_gemma":[0.9650058,0.019287165,0.0017636251,0.0033833121,0.008116985,0.000009159214,0.0000029189205,0.000040187475,0.002390856],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99843365,0.000056391702,0.0006034116,0.00014526784,0.00043982556,0.0003214776],"domain_scores_gemma":[0.9980382,0.000074535346,0.00094821793,0.0001854277,0.0003925026,0.00036113412],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001511106,0.00019213416,0.00058598944,0.00016343694,0.000069940186,0.00002783585,0.00014126401,0.000034208144,0.0014779875],"category_scores_gemma":[0.00003461158,0.00014578317,0.0002547263,0.0003386668,0.00027304448,0.00015992884,0.000015460566,0.00031677485,0.00019142931],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040474278,0.00029733437,0.048731185,0.00001785085,0.0035032593,0.00008991643,0.0027866815,0.00037855818,0.00011116097,0.00008461004,0.01983779,0.9237569],"study_design_scores_gemma":[0.003205973,0.0021675855,0.02947013,0.0006301231,0.0055711567,0.000058873688,0.0010907489,0.00007029078,0.00059452205,0.000020042504,0.9569237,0.00019684777],"about_ca_topic_score_codex":0.00033864746,"about_ca_topic_score_gemma":0.000056721285,"teacher_disagreement_score":0.9370859,"about_ca_system_score_codex":0.0006325289,"about_ca_system_score_gemma":0.0013317358,"threshold_uncertainty_score":0.99943477},"labels":[],"label_agreement":null},{"id":"W2334751043","doi":"10.2165/00024669-200403060-00003","title":"Hepatocellular Carcinoma","year":2004,"lang":"en","type":"article","venue":"American Journal of Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto","funders":"","keywords":"Medicine; Hepatocellular carcinoma; Cirrhosis; Hepatitis B; Internal medicine; Gastroenterology; Cancer; Viral hepatitis; Liver cancer","score_opus":0.031933780284345716,"score_gpt":0.27486328875050464,"score_spread":0.24292950846615893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2334751043","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99159896,0.004296292,0.00027496018,0.0028858343,0.00016516609,0.00011934948,0.0000029498824,0.000012084252,0.0006443705],"genre_scores_gemma":[0.99638915,0.00042775218,0.0019604047,0.00067027245,0.0004040954,0.000008185913,0.0000016731755,0.00002454854,0.00011391281],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989844,0.000026864138,0.00033000982,0.00011389798,0.00032882576,0.0002160206],"domain_scores_gemma":[0.9990454,0.00001840253,0.00030618682,0.00015222798,0.00021794485,0.00025985404],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012360948,0.00013555837,0.00043892674,0.00014237236,0.000037261612,0.000011750619,0.00008709739,0.000028420221,0.00018611313],"category_scores_gemma":[0.000017113935,0.00010145534,0.00026948602,0.000301231,0.00015270265,0.00007814811,0.000012267023,0.00018783098,0.000020390165],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024348995,0.00010578735,0.95239663,0.000013376751,0.00018202158,0.00094203436,0.00028254752,0.0000063960115,0.0027284832,0.00005901557,0.00012728138,0.04291292],"study_design_scores_gemma":[0.011456977,0.009674597,0.7741438,0.00060498447,0.0019914643,0.0027594182,0.0010100057,0.00021728768,0.15079255,0.00057769765,0.046174973,0.00059623003],"about_ca_topic_score_codex":0.00045850247,"about_ca_topic_score_gemma":0.0000057974726,"teacher_disagreement_score":0.17825283,"about_ca_system_score_codex":0.00023224494,"about_ca_system_score_gemma":0.0004972826,"threshold_uncertainty_score":0.41372287},"labels":[],"label_agreement":null}]}